Efficacy and safety of immunoglobulin associated with rituximab versus rituximab alone in Childhood-Onset steroid-dependent nephrotic syndrome
Phase of Trial: Phase II/III
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Immune globulin (Primary) ; Rituximab (Primary)
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- Acronyms RITUXIVIG
- 16 Apr 2019 Planned End Date changed from 15 Sep 2021 to 3 Apr 2022.
- 16 Apr 2019 Planned primary completion date changed from 16 Sep 2018 to 3 Apr 2020.
- 16 Apr 2019 Status changed from not yet recruiting to recruiting.